42 6. Literaturverzeichnis

1. Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women`s Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712

2. Aronow WS: Management of peripheral arterial disease. Cardiol Rev. 13 (2005) 6168

3. Barrett-Connor E: Cardiovascular endocrinology 3: an epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab. 88 (2003) 4031-4042

4. Barretto S, Ballmann KV, Rooke TW et al.: Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location. Vasc Med 8 (2003) 95-100

5. Becker BF, Heindl B, Kupatt C, et al.: Endothelial function and hemostasis. Z Kardiol 3 2000 160-167

6. Bergmark C, Mansoor MA, Swedenborg J, et al.: Hyperhomocysteinemia in patients operatet for lower extremity ischaemia below the age of 50: effect of smoking and extent of disease. Eur J Vasc Surg 7 (1993) 391-396

7. Blum A, Lupovitch S, Khazim K et al.: Homocysteine levels in patients with risk factors for atherosclerosis. Clin Cardiol 24 (2001) 463-466

8. Braunwald E, Zipes DP, Libby P, et al.: Braunwald`s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Elsevier Saunders, Philadelphia, 2005, p. 1951-1958

9. Brevetti G, Silvestro A, Schiano V et al.: Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flowmediated dilation to ankle-brachial pressure index. Circulation 108 (2003) 2093-2098

10. Butler RN: Population aging and health. BMJ 315 (1997) 1082-1084

43 11. Clarke R, Daly L, Robinson K, et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155

12. Cortellaro M, Cofrancesco E, Boschetti C, et al.: Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 13 (1993) 1412-1417

13. Cremer P, Nagel D, Labrot B, et al.: Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 129 (1997) 221-230

14. Daviglus ML, Liu K, Yan LL et al.: Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 292 (2004) 2743-2749

15. Davis CE, Williams DH, Oganov RG et al.: Sex difference in high density lipoprotein cholesterol in six countries. Am J Epidemiol 143 (1996) 1100-1106

16. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin: Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der BeckenBeinarterien, Stand Juli 2001. VASA 2001; Suppl 57

17. Diehm C, Kareem S, Lawall H: Epidemiology of peripheral arterial disease. VASA 33 (2004) 183-189

18. Diehm C, Schuster A, Allenberg JR, et al.: High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172 (2004) 95-105

19. Di Tullio MR, Sacco RL, Savoia MT, et al.: Gender differences in the risk of ischemic stroke associated with aortic atheromas. Stroke 31 (2000) 2623-2627

20. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622

44 21. Fechner L, Große L, Podhaisky H et al.: Untersuchungen zur klinischen Manifestation der peripheren arteriellen Verschlusskrankheit bei Diabetes mellitus. Herz Kreisl 30 (1998) 176-179

22. Feinglass J, McDermott MM, Foroohar M et al.: Gender differences in interventional management of peripheral vascular disease: evidence from a blood flow laboratory population. Ann Vasc Surg 8 (1994) 343-349

23. Gardner AW: Sex differences in claudication pain subjects with peripheral arterial disease. Med Sci Sports Exerc. 34 (2002) 1695-1698

24. Gerhard M, Baum P, Raby KE: Peripheral arterial-vascular disease in women: prevalence, prognosis, and treatment. Cardiology 86 (1995) 349-355

25. Grundy SM, Bazzare T, Cleeman J et al.: Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment. Writing Group I. Circulation 101 (2000) E3-E11

26. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes. Diabetes Care 22 (1999) 1887-1898

27. Herold G: Innere Medizin. Gerd Herold, Köln, 1999, S. 568

28. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Ciculation 91 (1995) 1472-1479

29. Higgins JP, Higgins JA: Peripheral arterial diseaseúPart I: Diagnosis, epidemiology and risk factors. J Okla State Med Assoc 95 (2002) 765-769

30. Hirsch AT, Criqui MH, Treat-Jacobson D et al.: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324

31. Holler D, Claes C, von der Schulenburg JM: Treatment costs and quality of life of patients with peripheral arterial occlusive disease – the German perspective. VASA 33 (2004) 145-153

45

32. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022

33. Hosoda S, Yaginuma T, Sugawara M, et al.: Recent Progress in Cardiovascular Mechanismus, Harwood Academic Publishers, Newark, NJ, K, 1994, 115-128

34. Hu F, Grodstein F: Postmenopausal hormone therapy and the risk of cardiovascular disease: The epidemiologic evidence. Am J Cardiol 90 (2002) 26F-29F

35. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613

36. Ingolfsson IO, Sigurdsson G, Sigvaldason H et al.: A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol – The Reykjavik Study. J Clin Epidemiol 47 (1994) 1237-1247

37. Jager A, Kostense PJ, Ruhe HG et al.: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all – cause mortalitiy, especially among hypertensive subjects: five – year follow – up of the Hoorn Study. Arterioscler Thromb Vasc Biol 19 (1999) 617-624

38. Jude EB, Oyibo SO, Chalmers N, et al.: Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 24 (2001) 1433-1437

39. Juhan-Vague I, Pyke SD, Alessi MC, et al.: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063

46 40. Kannel WB, D`Agostino RB, Wilson PWF, et al.: Diabetesfibrinogen and the risk on cardiovascular disease: the Framingham experience. Am Heart J 120 (1990) 672676

41. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 33 (1985) 13-18

42. Kassner U, Thomas HP, Steinhagen-Thiessen E: Lipoprotein(a): Epidemiologie und therapeutische Ansätze. Dtsch Med Wschr 125 (2000) 1337-1343

43. Kasper DL, Braunwald E, Fauci AS, et al.: Harrison`s Principles of Internal Medicine. 16 th ed. The McGraw-Hill Companies, Berlin, 2005

44. Kirkland S, Greaves L, Devichand P: Gender Differences in Smoking and Self Reported Indicators of Health. BMC Womens Health 4 (2004) Suppl 1:S7

45. Koolman J, Röhm KH: Taschenatlas der Biochemie. Thieme, Stuttgart, New York, 1994, S. 180

46. Kroger K: Dyslipoproteinemia and peripheral arterial occlusive disease. Angiology 55 (2004) 135-138

47. Kröger K, Suckel A, Hirche H et al.: Different prevalence of asymptomatic atherosclerotic lesions in males and females. Vasc Med 4 (1999) 61-65

48. Kronenberg F, Kronenberg MF, Kiechl S, et al.: Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160

49. Labarrere CA: Relationsship of fibrin deposition in microvasculature to outcomes in cardiac transplantation. Curr Opin Cardiol 14 (1999) 133-139

50. LaRosa JC: Lipids. In Douglas PS (ed): Cardiovascular Health and Disease in Women. 2nd ed. WB Saunders, Philadelphia, 2002, pp 23-28

47 51. Legato MJ: Gender-specific physiology: How real it is? How important it is? Int J Fertil Womens Med 42 (1997) 19-29

52. Lohr M, Keppler B (a): Innere Medizin. 3. Aufl. Urban & Fischer, München, Jena, 2000, S. 497-499

53. Lohr M, Keppler B (b): Innere Medizin. 3. Aufl. Urban & Fischer, München, Jena, 2000, S. 180

54. Malarcher AM, Schulman J, Epstein LA, et al. : Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol 152 (2000) 573-584

55. Manson JE, Willett WC, Stampfer MJ, et al.: Body weight and mortality among women. N Engl J Med 333 (1995) 677-685

56. McDermott MM, Fried L, Simonsick E et al.: Asymptomatic peripheral arterial disaese is independently associated with impaired lower extremity functioning: the women`s health and aging study. Circulation 101 (2000) 1007-1012

57. McDermott MM, Greenland P, Liu K et al.: Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc 51 (2003) 222-228

58. Mendelsohn ME: Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90 (2002) 3F-6F

59. Murabito JM, D`Agostino RB, Silbershatz H, et al.: Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 96 (1997) 44-49

60. Newman AB: Peripheral arterial disease: insights from population studies of older adults. J Am Geriatr Soc 48 (2000) 1157-1162

61. Newman AB, Shemanski L, Manolio TA et al.: Ankle-Arm Index as a Predictor of Cardiovaskular Disease and Mortalitiy in the Cardiovascular Health Study. Arteriosclerosis, Thrombosis and Vascular Biology 19 (1999) 538 – 545

48 62. Newman AB, Siscovick DS, Manolio TA et al.: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 88 (1993) 837-845

63. Nguyen L, Liles DR, Lin PH, et al.: Hormone replacement therapy and peripheral vascular disease in women. Vasc Endovascular Surg 38 (2004) 547-556

64. Nikkila M, Pitkajarvi T, Koivula T et al.: Women have a larger and less atherogenic low density lipoprotein particle size than men. Atherosclerosis 119 (1996) 181-190

65. Norman PE, Semmens JB, Lawrence-Brown M et al.: The influence of gender on outcome following peripheral vascular surgery: a review. Cardiovasc Surg 8 (2000) 111-115

66. O`Donnel CJ, Lindpaintner K, Larson MG, et al.: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97 (1998) 1766-1772

67. O`Hare AM, Vittinghoff E, Hsia J et al.: Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 15 (2004) 1046-1051

68. Oka RK, Szuba A, Giacomini et al.: Gender differences in perception of PAD: a pilot study. Vasc Med 8 (2003) 89-94

69. Parsi RA, Parsi E: Kardiologie Angiologie. 1. Aufl. Urban & Fischer Verlag, München, Jena, 2001, S.809

70. Perry IJ: Homocystein, hypertension and stroke. J Hum Hyperten 13 (1999) 289293

71. Podhaisky M, Hänsgen K, Taute BM: Systemische Atherosklerose bei peripherer arterieller Verschlusskrankheit. Perfusion 16 (2003) 212-216

49 72. Reinhart WH: Fibrinogen – marker or mediator of vascular disease? Vasc Med 8 (2003) 211-216

73. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C – reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485

74. Rieger H, Schoop W: Klinische Angiologie. Springer, Berlin, Heidelberg, New York, 1999

75. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women`s Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333

76. Safar ME, Smulyan H: Hypertension in women. Am J Hypertens 17 (2004) 82-87

77. Sherry B, Mei Z, Scanlon KS et al.: Trends in state-specifc prevalence of overweight and underweight in 2-through 4-year-old children from low-income families from 1989 through 2000. Arch Pediatr Adolesc Med 158 (2004) 1116-1124

78. Silaste ML, Junes R, Rantala AO, et al.: Dietary and other non-pharmacological treatments in patients with drug-treated hypertension and control subjects. J Intern Med 247 (2000) 318-324

79. Skerrett PJ, Spelsberg A, Manson JE: Carbohydrate metabolism, obesity and diabetes mellitus. In Douglas PS (ed): Cardiovascular Health and Disease in Women. 2nd ed. WB Saunders, Philadelphia, (2002), pp. 39-70

80. Slovina K: Vaskuläre Komplikationen an der Punktionsstelle bei perkutanen transluminalen arteriellen Eingriffen. Med. Inaug.-Diss., Techn. Universität Dresden (2005)

81. Smulyan H, Asmar RG, Rudnicki A, et al.: Comparative effects of aging in men and women on the properties of the arterial tree. J Am Coll Cardiol 37 (2001) 13741380

50

82. Socha MW, Polakowska MJ, Socha-Urbanek K, et al.: Hyperhomocysteinemia as a risk factor for cardiovascular disease. The association of hyperhomocysteinemia with diabetes mellitus and renal transplant recipients. Ann Transplant 4 (1999) 11-19

83. Stampfer MJ, Colditz GA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from nurses` health study. N Engl J Med 325 (1991) 756-762

84. Stoffers HE, Rinkens PE, Kester AD et al.: The prevalence of asymptomatic and unrecognized peripheral arterial occlussive disease. Int J Epidemiol 25 (1996) 282-290

85. Strano A, Novo S, Licata G et al.: Asymptomatic and symptomatic carotid and peripheral arterial disease in patients suffering from CHD. Factors affecting the progression of atherosclerosis. In: Vascular Medicine. Boccalon H, eds. Excepta Medica, Amsterdam, 1993, pp. 275 – 278

86. Taute BM, Taute R, Heins S, et al.: Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int Angiol 23 (2004) 35-40

87. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter - Society Consensus (TASC). J Vasc Surg 31 (2000) S1-S296

88. Temelkova – Kurktschiev T, Fischer S, Koehler C et al.: Intima – Media – Dicke bei Gesunden ohne Risikofaktoren für Atherosklerose. Dtsch Med Wochenschr 126 (2001) 193-197

89. Tsiara S, Elisaf M, Mikhailidis DP: influence of smoking on predictors of vascular disease. Angiol 54 (2003) 507-530

90. UKPDS Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853

51 91. Vogt MT, Cauley JA, Kuller LH et al.: Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol 137 (1993) 559-568

92. Vogt MT, Cauley JA, Newmann AB et al.: Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270 (1993) 465-469

93. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol 45 (1992) 529-542

94. Weksler B: Hemostasis and thrombosis. In Douglas PS (ed): Cardiovascular Health and Disease in Women. 2nd ed. WB Saunders, Philadelphia, 2002, pp 157-177

95. Wenger NK: Coronary heart disease and women: magnitude of the problem. Cardiol Rev 10 (2002) 211-213

96. Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensinconverting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592

97. Wuillemin WA, Solenthaler M: Hyperhomocysteinämie: Risikofaktor für arterielle und venöse thrombotische Erkrankungen. VASA 28 (1999) 151-155

98. Zanger D, Yang BK, Ardans J, et al.: Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 36 (2000) 1797-1802

99. Yano K, Grove JS, Chen R et al.: Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 21 (2001) 1065-1070